Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other ant...Show More
peer of
Metrics
marketSTOCKS
msh_idCOM:ONCONOVA
localeus
websitehttps://www.onconova.com/
ipo_date2013-07-25
primary_stock_msh_idNASDAQ:ONTX
source_reff19644e8-38e7-4b72-9853-bed3f4d6706b
products_or_servicesNarazaciclib (ON 123300) and oral rigosertib; targeted anti-cancer agents.